Myasthenia gravis (MG) is an autoimmune disorder with bimodal age of presentation, occurring in young women of reproductive age and at an older age in men. Occasionally, MG is diagnosed during pregnancy. Management of MG includes symptomatic treatment with cholinesterase inhibitors and immunosuppressive therapy for controlling the disease activity. Treatment of MG in women of reproductive age, who may be contemplating pregnancy, requires discussion regarding the choice of medication as well as the understanding of risks/adverse effects involved with various treatments. During the peripartum period, it is essential to ensure careful monitoring of the disease state along with the well‐being of the mother and fetus and to coordinate neonatal monitoring overseen by a multidisciplinary team comprising a high‐risk maternal fetal medicine specialist, a neurologist familiar with these complex issues, and a neonatologist.

All conflicts of interest have been resolved according to ACCME standards. All authors/planners of this activity had nothing to disclose.